Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Larimar Therapeutics (LRMR) Cash & Equivalents (2016 - 2020)

Larimar Therapeutics (LRMR) has disclosed Cash & Equivalents for 7 consecutive years, with $43.3 million as the latest value for Q3 2019.

  • For the quarter ending Q3 2019, Cash & Equivalents fell 4.0% year-over-year to $43.3 million, compared with a TTM value of $43.3 million through Sep 2019, down 4.0%, and an annual FY2018 reading of $49.3 million, up 20.98% over the prior year.
  • Cash & Equivalents was $43.3 million for Q3 2019 at Larimar Therapeutics, up from $37.2 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $106.9 million in Q1 2015 and bottomed at $19.2 million in Q3 2017.
  • Average Cash & Equivalents over 5 years is $41.7 million, with a median of $37.2 million recorded in 2019.
  • The sharpest move saw Cash & Equivalents surged 177.87% in 2015, then tumbled 76.04% in 2016.
  • Year by year, Cash & Equivalents stood at $35.6 million in 2015, then dropped by 9.11% to $32.4 million in 2016, then grew by 26.04% to $40.8 million in 2017, then increased by 20.98% to $49.3 million in 2018, then fell by 12.15% to $43.3 million in 2019.
  • Business Quant data shows Cash & Equivalents for LRMR at $43.3 million in Q3 2019, $37.2 million in Q2 2019, and $36.4 million in Q1 2019.